Enopace Biomedical

Company Overview

Snapshot

Founded in October 2007 by Yossi Gross, Enopace Biomedical operated with 11–50 employees. The company raised $25 million across three funding rounds from Sorin. In February 2025, Enopace Biomedical ceased to operate.

Business overview

Enopace Biomedical developed a device to treat patients with heart failure. The company's core technology, the Harmony™ System, was a minimally invasive, implantable neurostimulation device designed to increase cardiac efficiency by reducing left-ventricular workload. This system provided precise and personalized aortic stimulation, with a wearable unit allowing users to control therapy as needed. The device was designed for quick implantation in a standard catheterization procedure without general anesthesia, serving the cardiology and medical device sectors within the Health Tech & Life Sciences industry.

Strategic signal

Enopace Biomedical ceased operations in February 2025, indicating a significant shift in its trajectory. This event signals to investors and innovation teams that the company's development of its minimally invasive neurostimulation device for heart failure has concluded, impacting the landscape of medical device innovation in this specific therapeutic area.

Company Intelligence Q&A

What is the primary focus of Enopace Biomedical?

Enopace Biomedical focused on developing a minimally invasive neurostimulation device, the Harmony™ System, for the treatment of heart failure patients.

When was the company founded?

Enopace Biomedical was founded in October 2007.

What was the company's operational status as of February 2025?

As of February 2025, Enopace Biomedical ceased to operate.

Which investor participated in Enopace Biomedical's funding rounds?

Sorin participated as an investor in Enopace Biomedical's funding rounds, including a $7 million investment in October 2011 and a $13 million investment in February 2013.

What was a key product developed by Enopace Biomedical?

Enopace Biomedical developed the Harmony™ System, an endovascular neuromodulation device designed for the treatment of congestive heart failure, which saw its first human implantation in November 2015.